PURPOSE: To assess the long-term safety, efficacy, predictability, and stability of conductive keratoplasty (CK) for the treatment of low to moderate hyperopia and to evaluate the impact of the procedure on the quality of vision. SETTING: University of Crete, Medical School, Vardinoyannion Eye Institute of Crete, Crete, Greece. METHODS: In this prospective nonrandomized noncontrolled single-center study, 38 eyes of 26 patients (13 women and 13 men) were treated for hyperopia with a Refractec ViewPoint CK system and followed for 30 months. Preoperatively, the mean manifest refraction spherical equivalent (MRSE) was +1.89 diopters (D) +/- 0.6 (SD) (range +1.00 to +3.25 D), and the mean follow-up was 30.9 +/- 1.1 months. All eyes were treated with the regular CK nomogram for the treatment of spherical hyperopia. The treatment consisted of 8 to 32 spots applied to the periphery of the cornea. Mean age was 50.3 +/- 8.8 years (range 31 to 71 years). All treated eyes were analyzed for safety, efficacy, predictability, and stability. RESULTS: At 12 months, the MRSE was -0.06 +/- 0.8 D and at 30 months was -0.02 +/- 0.7 D. At 30 months, the mean MRSE was within +/-0.50 D in 68%, within +/-1.00 D in 92%, and within +/-2.00 D in all eyes. At 30 months, uncorrected visual acuity was 20/20 or better in 52.5% and 20/40 or better in 89% of eyes. No eye lost 2 or more Snellen lines or had an induced cylinder of 2.00 D or greater. The procedure did not cause statistically significant changes in contrast sensitivity. CONCLUSION: Results show that CK for low to moderate hyperopia is a safe, effective, predictable, and stable procedure.
PURPOSE: To assess the long-term safety, efficacy, predictability, and stability of conductive keratoplasty (CK) for the treatment of low to moderate hyperopia and to evaluate the impact of the procedure on the quality of vision. SETTING: University of Crete, Medical School, Vardinoyannion Eye Institute of Crete, Crete, Greece. METHODS: In this prospective nonrandomized noncontrolled single-center study, 38 eyes of 26 patients (13 women and 13 men) were treated for hyperopia with a Refractec ViewPoint CK system and followed for 30 months. Preoperatively, the mean manifest refraction spherical equivalent (MRSE) was +1.89 diopters (D) +/- 0.6 (SD) (range +1.00 to +3.25 D), and the mean follow-up was 30.9 +/- 1.1 months. All eyes were treated with the regular CK nomogram for the treatment of spherical hyperopia. The treatment consisted of 8 to 32 spots applied to the periphery of the cornea. Mean age was 50.3 +/- 8.8 years (range 31 to 71 years). All treated eyes were analyzed for safety, efficacy, predictability, and stability. RESULTS: At 12 months, the MRSE was -0.06 +/- 0.8 D and at 30 months was -0.02 +/- 0.7 D. At 30 months, the mean MRSE was within +/-0.50 D in 68%, within +/-1.00 D in 92%, and within +/-2.00 D in all eyes. At 30 months, uncorrected visual acuity was 20/20 or better in 52.5% and 20/40 or better in 89% of eyes. No eye lost 2 or more Snellen lines or had an induced cylinder of 2.00 D or greater. The procedure did not cause statistically significant changes in contrast sensitivity. CONCLUSION: Results show that CK for low to moderate hyperopia is a safe, effective, predictable, and stable procedure.